H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 20.14 CNY -0.74% Market Closed
Market Cap: 12.1B CNY
Section:
 

Relative Value

The Relative Value of one Hualan Biological Bacterin Inc stock under the Base Case scenario is 31.94 CNY. Compared to the current market price of 20.14 CNY, Hualan Biological Bacterin Inc is Undervalued by 37%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
31.94 CNY
Undervaluation 37%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

12.2
P/S
P/S
Price to Sales
12.2
vs History
10
vs Industry
54
Median 3Y
9.3
Median 5Y
9.1
Industry
7.9
Forward
6.6
More Details
171.8
P/E
P/E
Price to Earnings
171.8
vs History
4
vs Industry
7
Median 3Y
33.6
Median 5Y
30.7
Industry
23.7
Forward
18.6
More Details
40.4
P/OCF
P/OCF
Price to OCF
40.4
vs History
27
vs Industry
12
Median 3Y
25.8
Median 5Y
28.1
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
10
Median 3Y
18
Median 5Y
16
Industry
23.8
More Details
2
P/B
P/B
Price to Book Value
2
vs History
60
vs Industry
46
Median 3Y
2.1
Median 5Y
2.3
Industry
3.3
More Details
9.1
EV/S
EV/S
Enterprise Value to Sales
9.1
vs History
18
vs Industry
49
Median 3Y
7.3
Median 5Y
6.8
Industry
8.3
Forward
4.9
More Details
11.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.7
vs History
14
vs Industry
50
Median 3Y
9.1
Median 5Y
8.9
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
8
Median 3Y
27.3
Median 5Y
23.6
Industry
6.4
Forward
9.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
7
Median 3Y
27.3
Median 5Y
23.6
Industry
7
Forward
12.1
More Details
30.2
EV/OCF
EV/OCF
Enterprise Value to OCF
30.2
vs History
35
vs Industry
12
Median 3Y
21.9
Median 5Y
23.9
Industry
8.3
More Details
32
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
32
vs History
16
vs Industry
9
Median 3Y
22.7
Median 5Y
18
Industry
6.5
More Details
2.4
EV/IC
EV/IC
Enterprise Value to IC
2.4
vs History
54
vs Industry
50
Median 3Y
2.4
Median 5Y
2.6
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
Hualan Biological Bacterin Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Hualan Biological Bacterin Inc
SZSE:301207
12.1B CNY 12.2 171.8 -309.7 -309.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 798 004.3 -160 636.9 -195 064.4 -192 838.5
US
Abbvie Inc
NYSE:ABBV
394.7B USD 6.6 168.1 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
170.9B USD 4.8 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD 5.1 18.4 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.4 -531.9 -579.2 -563.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
45.9B EUR 15 35.2 60.9 62.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 202.7 158 191.6
P/E Multiple
Earnings Growth PEG
CN
H
Hualan Biological Bacterin Inc
SZSE:301207
Average P/E: 187.6
171.8
74%
2.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 636.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
35.2
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 202.7
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
H
Hualan Biological Bacterin Inc
SZSE:301207
Average EV/EBITDA: 39.7
Negative Multiple: -309.7
111%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 064.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
60.9
839%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
H
Hualan Biological Bacterin Inc
SZSE:301207
Average EV/EBIT: 45.8
Negative Multiple: -309.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 838.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.5
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.